Boey®: The New Fast-Acting Botox Approved in Europe. What You Need to Know

If you've been following aesthetic medicine recently, you may have seen headlines about a new botulinum toxin called Boey® that has just been approved in Europe.

Some articles have described it as "the world's first fast-acting Botox."

Others are calling it the biggest innovation in anti-wrinkle treatments for years.

So...

What exactly is Boey?

How is it different from Botox?

Is it coming to the UK?

And perhaps most importantly...

Is it actually better?

Let's separate the facts from the headlines.

Isn't Botox just... Botox?

Not quite.

When most people say "Botox", they're usually referring to any anti-wrinkle injection.

In reality, Botox® is simply one brand of botulinum toxin type A.

Other type A products available in the UK include:

• Botox®

• Bocouture®

• Azzalure®

• Alluzience®

• Letybo®

Boey is different.

Its active ingredient is trenibotulinumtoxinE, making it the first botulinum toxin type E authorised in Europe for cosmetic use (European Medicines Agency, 2026).

Although both type A and type E toxins temporarily relax muscles, they behave differently once injected.

That difference is exactly why Boey is attracting so much attention.

What makes Boey different?

Traditional anti-wrinkle treatments usually:

• begin working after around 2 to 5 days

• reach maximum effect after approximately 2 weeks

• last around 3 to 4 months, although everyone is different.

Boey has been designed to do almost the opposite.

Clinical trials found that some patients began showing improvement as early as eight hours after treatment, with the treatment typically lasting around two to three weeks (AbbVie, 2026).

Notice the wording.

It doesn't mean everyone will see results in eight hours.

It means measurable improvement was seen in some participants at the earliest assessment point.

That distinction is important.

Wait... why would anyone want a treatment that wears off so quickly?

It's probably the first question most injectors ask.

After all...

One of the biggest reasons patients love anti-wrinkle treatment is because it lasts for months.

So why would anyone choose something lasting only a few weeks?

Actually...

There are quite a few situations where it could make sense.

Imagine you've never had Botox before.

You might be wondering:

"What if I don't like it?"

"Will I look frozen?"

"Will everyone notice?"

Instead of committing to three or four months, Boey could potentially allow patients to experience anti-wrinkle treatment for a much shorter period before deciding whether longer-lasting treatment is right for them.

It's easy to understand why Allergan Aesthetics has described it as a potential "try before you commit" treatment (AbbVie, 2026).

Does that mean Boey is better?

No.

It means it's different.

For most established anti-wrinkle patients, three or four months of results is actually one of the treatment's biggest advantages.

Longer duration means:

• fewer appointments

• fewer injections

• less disruption

• better long-term value.

If you're already happy with your current treatment, Boey probably isn't designed to replace it.

Instead, it appears to fill a niche that hasn't really existed before.

Is Boey available in the UK?

This is where some headlines become slightly misleading.

Boey has received European Commission marketing authorisation, making it authorised across the European Economic Area through the centralised approval process (European Commission, 2026).

However...

That does not automatically mean it is available in Great Britain.

Following Brexit, medicines licensing in Great Britain is handled separately by the Medicines and Healthcare products Regulatory Agency (MHRA).

At the time of writing, Boey has not been launched for routine aesthetic use in Great Britain.

So yes...

It has been approved in Europe.

But that doesn't necessarily mean you'll be able to book it at your local clinic tomorrow.

Is it safe?

Every new injectable treatment naturally raises questions about safety.

The European approval was based on a clinical development programme involving more than 2,100 participants, including two pivotal Phase 3 clinical trials and a long-term safety study (AbbVie, 2026).

After reviewing the available evidence, the European Medicines Agency concluded that the benefits outweighed the known risks for its approved cosmetic indication (European Medicines Agency, 2026).

That's reassuring.

However, it's also worth remembering that products such as Botox®, Bocouture® and Azzalure® have decades of real-world experience behind them.

Boey doesn't yet have that same history.

Every treatment has to start somewhere.

Will Mr Beautox Aesthetics be offering Boey?

At the moment...

No.

Not because I think it's a bad product.

Quite the opposite.

I actually think it's one of the most exciting developments we've seen in aesthetic medicine for several years.

But I've always believed that new doesn't automatically mean better.

When new products arrive, I prefer to watch how they perform outside clinical trials before deciding whether they're right for my patients.

Independent research.

Real-world outcomes.

Long-term safety.

Patient satisfaction.

Those things matter just as much as regulatory approval.

So for now...

I'll be watching with genuine interest.

The real takeaway

Boey isn't trying to replace Botox.

It's trying to offer something completely different.

A fast-acting treatment with a much shorter duration could appeal to people who are curious about anti-wrinkle injections but aren't yet ready to commit to several months of results.

Whether it becomes a mainstream treatment remains to be seen.

But it's certainly one of the most interesting developments in aesthetics for many years, and I'll be following its progress closely as more research and real-world experience become available.

Frequently Asked Questions

What is Boey?

Boey® is the brand name for trenibotulinumtoxinE, the first botulinum toxin type E approved in Europe for the temporary improvement of moderate to severe glabellar (frown) lines.

Is Boey the same as Botox?

No.

Botox® is a botulinum toxin type A.

Boey® is a botulinum toxin type E.

Although both temporarily relax muscles, they have different characteristics, particularly in how quickly they start working and how long they last.

How quickly does Boey work?

Clinical trials found that some patients showed improvement as early as eight hours after treatment.

Most traditional botulinum toxin type A products usually begin working over the following few days.

How long does Boey last?

Current evidence suggests approximately two to three weeks.

Traditional botulinum toxin type A products typically last around three to four months, although this varies between individuals.

Is Boey available in the UK?

Not at present.

Although it has received European Commission marketing authorisation, it has not yet been launched for routine aesthetic use in Great Britain.

Will Mr Beautox Aesthetics be offering Boey?

Not currently.

I'll continue monitoring the research, UK regulatory position and real-world clinical experience before deciding whether it's a product I'd introduce into the clinic.

Thinking about anti-wrinkle treatment?

Whether you're completely new to anti-wrinkle injections or you've been enjoying them for years, choosing the right treatment isn't about following the latest trend. It's about finding the treatment that's right for you.

At Mr Beautox Aesthetics, every consultation is tailored to your goals, lifestyle and expectations. My approach is evidence based, honest and focused on achieving natural-looking results while keeping up to date with the latest developments in aesthetic medicine.

If you'd like to discuss anti-wrinkle treatments, or you're curious about emerging innovations like Boey, I'd be delighted to help.

🌐 www.mrbeautox.co.uk 📧 hello@mrbeautox.co.uk 📱 07902 245304

Written by Injector Rick at Mr Beautox Aesthetics, Worthing.

Because understanding the science behind aesthetic medicine is just as important as achieving great results.

References:

AbbVie (2026) Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), the first and only rapid-onset, short-duration neurotoxin, for use in Europe. Available at: https://news.abbvie.com (Accessed: 21 July 2026).

European Commission (2026) Community Register of Medicinal Products for Human Use: Boey (trenibotulinumtoxinE). Available at: https://ec.europa.eu/health/documents/community-register (Accessed: 21 July 2026).

European Medicines Agency (2026) Boey (trenibotulinumtoxinE): European Public Assessment Report (EPAR). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/boey (Accessed: 21 July 2026).

Pellett, S., Tepp, W.H. and Johnson, E.A. (2015) 'Botulinum neurotoxins: Biology, pharmacology and therapeutic applications', Handbook of Experimental Pharmacology, 227, pp. 63-89.